Rationale: Mitochondrial uncoupling proteins (UCPs) belong to a superfamily of mitochondrial anion transporters that uncouple ATP synthesis from oxidative phosphorylation and mitigates mitochondrial reactive oxygen species production. Objective: We assessed the hypothesis that UCP2 participates in central cardiovascular regulation by maintaining reactive oxygen species homeostasis in the rostral ventrolateral medulla (RVLM), where sympathetic premotor neurons that maintain vasomotor tone located. We also elucidated the molecular mechanisms that underlie transcriptional upregulation of UCP2 in response to oxidative stress in RVLM.
L iving organisms possess a variety of physiological protective mechanisms to counteract oxidative stress and to restore redox balance. Oxidative damage to cells that results from an imbalance of production over degradation of the reactive oxygen species (ROS), particularly superoxide anion (O 2 Ϫ⅐ ) and hydrogen peroxide (H 2 O 2 ), is associated with a variety of cardiovascular diseases, including heart failure, atherosclerosis, and hypertension. [1] [2] [3] Of note is that overproduction of O 2 Ϫ⅐ and H 2 O 2 in the central nervous system contributes to neural mechanisms of hypertension by increasing sympathetic outflow to the peripheral blood vessels. 4, 5 In addition to the degradative enzymes (eg, superoxide dismutase [SOD] and catalase) and low-molecular-weight antioxidants (eg, ascorbic acid and glutathione), the uncoupling proteins (UCPs) have emerged as important natural antioxidants in the maintenance of ROS homeostasis. 6 UCPs belong to a superfamily of mitochondrial anion transporters that uncouple ATP synthesis from oxidative phosphorylation by causing proton leakage across the mitochondrial inner membrane, leading to energy dissipation and heat production. 7 More importantly, the resultant decrease in proton electrochemical gradient across the inner mitochondrial membrane elicited by the UCPs mitigates mitochondrial ROS production. 6, 8 In mammals, 5 homologues, UCP1 to UCP5, have so far been cloned. 9 Among them, dysfunction of UCP2 is suggested to be of considerable importance in cardiovas-cular pathophysiology associated with oxidative stress. Knockdown of ucp2 gene increases mitochondrial membrane potential and ROS production in murine endothelial cells. 10 Oxidative stress is also greater in the thoracic aorta of mice that are subject to bone marrow transplant derived from UCP2 Ϫ/Ϫ mice. 11 Adenovirus-mediated overexpression of UCP2, on the other hand, decreases ROS generation in human aortic endothelial cells. 12 In the rostral ventrolateral medulla (RVLM), where sympathetic premotor neurons for the maintenance of vasomotor tone are located, 13 emerging evidence supports a pivotal role for oxidative stress in neural mechanism of hypertension. 4, 5, 14 On the other hand, whereas UCP2 is expressed in a wide array of tissues, including the brain, 15 the physiological significance of its antioxidant role in central regulation of cardiovascular phenotypes is yet to be identified. The present study was undertaken to assess the hypothesis that mitochondrial UCP2 participates in central cardiovascular regulation by maintaining ROS homeostasis in RVLM. We also elucidated the molecular mechanisms that underlie transcriptional regulation of UCP2 expression in response to oxidative stress in RVLM.
Methods
An expanded Methods section is available in the Online Data Supplement http://circres.ahajournals.org.
Animals
Experiments were carried out in adult male Sprague-Dawley rats (280 to 305 g, nϭ345) purchased from the Experimental Animal Center of the National Applied Research Laboratories, Taiwan. All experimental procedures were carried out in compliance with the guidelines of our institutional animal care committee.
PPAR␥-Dependent Transcriptional Upregulation of Mitochondrial UCP2 in RVLM
Upregulation of mitochondrial UCP2 expression in RVLM was elicited by microinjection bilaterally of an activator of its transcription factor PPAR␥, rosiglitazone into this medullary site. Ligand specificity was ascertained by comicroinjection of a selective PPAR␥ inhibitor, GW9662. The temporal changes in UCP2 mRNA or protein expression in RVLM after rosiglitazone treatment were determined by real-time RT-PCR and Western blot analysis.
Reduction in Oxidative Stress and Arterial Pressure After Transcriptional Upregulation of Mitochondrial UCP2 in RVLM
The effect of transcriptional upregulation of UCP2 on mitochondrial level of H 2 O 2 in RVLM and basal systemic arterial pressure (SAP) was examined at various time intervals after microinjection bilaterally into RVLM of rosiglitazone. H 2 O 2 in the mitochondrial fraction was measured by an Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Molecular Probe, Eugene, Ore). SAP was determined under conscious conditions by radiotelemetry. 16 The specificity of PPAR␥-induced transcriptional upregulation of UCP2 on H 2 O 2 production in RVLM or SAP was confirmed by coadministration of GW9662.
Transcriptional Upregulation of Mitochondrial UCP2 Expression in RVLM by O 2

؊⅐
We reported previously that angiotensin II (Ang II) induces O 2 Ϫ⅐ production in RVLM via activation of NADPH oxidase. 17 To evaluate the role of NADPH oxidase-derived O 2 Ϫ⅐ in the expression of mitochondrial UCP2, Ang II was microinjected bilaterally into RVLM, alone or together with a NADPH oxidase inhibitor, diphenyleneiodonium chloride (DPI) (1 nmol); a SOD mimetic, tempol (50 nmol); or by gene knockdown of p22 phox or p47 phox subunit of the NADPH oxidase with their respective antisense oligonucleotide (ASON) (100 pmol). 17 The involvement of cytosolic or mitochondrial O 2
Ϫ⅐ in Ang II-induced mitochondrial UCP2 expression was further confirmed in animals that received gene transfer into RVLM of adenovirus encoding the cytosolic copper/zinc SOD (AdSOD1), mitochondrial manganese SOD (AdSOD2), or catalase (AdCAT). 5 The specificity and efficacy of p22 phox and p47 phox ASON 17 and AdSOD1, AdCAT, or AdSOD2 5 have been characterized in our previous studies.
Involvement of Mitogen-Activated Protein Kinases in Transcriptional Upregulation of UCP2 in RVLM by O 2
؊⅐
We reported previously 16, 17 that activation of p38 mitogen-activated protein kinase (p38 MAPK) and extracellular signal-regulated protein kinase (ERK)1/2 by NADPH oxidase-derived O 2 Ϫ⅐ mediates the cellular responses to Ang II in RVLM. To examine the engagement of these 2 signaling molecules in transcriptional regulation of UCP2 by O 2 Ϫ⅐ , the temporal expression of UCP2 mRNA or protein in RVLM was determined on coadministration of p38 MAPK or ERK1/2 inhibitor SB203580 or U0126 bilaterally into RVLM with Ang II.
Phosphorylation of PGC-1␣ by MAPKs and UCP2 Upregulation in RVLM
We determined whether PGC-1␣, a PPAR-interacting protein for the induction of UCP2, 18 
Protective Role for UCP2 Against Ang II-Induced Pressor Response and Oxidative Stress in RVLM
We established a protective role for O 2 Ϫ⅐ -dependent transcriptional activation of mitochondrial UCP2 in central cardiovascular regulation and ROS homeostasis in RVLM by determining the effect of microinjection into the bilateral RVLM or intracisternal infusion (1 or 5 g ⅐ L Ϫ1 ⅐ h Ϫ1 ) by osmotic minipump of rosiglitazone or an ASON against UCP2 on pressor responses to chronic intracerebroventricular (ICV) infusion of Ang II for 7 days and the elicited elevation in H 2 O 2 in RVLM.
ROS Production and SAP After Transcriptional Downregulation of Mitochondrial UCP2 in RVLM
We investigated whether mitochondrial UCP2 in RVLM participates in tonic regulation of tissue level of ROS or SAP by determining the effect of microinjection bilaterally into RVLM of UCP2 ASON on mitochondrial level of H 2 O 2 or SAP. The effectiveness of gene knockdown of UCP2 was confirmed by real-time RT-PCR analysis or Western blot analysis.
Mitochondrial Respiratory Enzyme Activity and Tissue ATP Content After Transcriptional Up-or Downregulation of Mitochondrial UCP2 in RVLM
The effect of microinjection bilaterally into RVLM of rosiglitazone or UCP2 ASON on enzyme activity of mitochondrial respiratory complex I to V, electron-coupling capacity between respiratory complexes, or tissue level of ATP in RVLM was assessed. Enzyme activity of mitochondrial respiratory complex I to V, NADH cytochrome c reductase (marker for electron coupling capacity between complexes I and III) or succinate cytochrome c reductase (marker for electron coupling capacity between complexes II and III) was determined by spectrophotometry. 19 Tissue ATP concentration was measured by an ATP bioluminescence assay. 19 
Statistical Analysis
Data are expressed as meansϮSEM. The statistical software Sig-maStat (SPSS, Chicago, Ill) was used for data analysis. One-way or 2-way ANOVA with repeated measures was used to assess group means, as appropriate, to be followed by the Scheffé multiple-range test for post hoc assessment of individual means. PϽ0.05 was considered statistically significant.
Results
Transcriptional Upregulation of Mitochondrial UCP2 in RVLM by PPAR␥ Activator
The fundamental premise for UCP2 to play a role in ROS homeostasis in RVLM and cardiovascular regulation is its presence in this neural substrate. Results from our first series of experiments established this premise by showing a moderate basal expression of UCP2 mRNA or protein in the mitochondrial fraction of tissues from RVLM ( Figure 1 ). We further showed that determined 6 or 12 hours postinjection, microinjection bilaterally into RVLM of rosiglitazone (1 or 5 nmol), an activator of the transcription factor PPAR␥, significantly upregulated UCP2 mRNA ( Figure 1A ) or protein ( Figure 1B ) expression. Comicroinjection bilaterally into RVLM of a PPAR␥ antagonist, GW9662 (100 or 500 pmol), discernibly attenuated the induced upregulation of UCP2 protein expression by rosiglitazone (5 nmol) ( Figure 1C ). GW9662 alone, however, did not affect UCP2 protein level in RVLM.
Transcriptional Activation of Mitochondrial UCP2 Decreases H 2 O 2 Level in RVLM and Reduces SAP
Our second series of experiments investigated whether transcriptional upregulation of UCP2 regulates tissue level of ROS in RVLM. Given the abundance of manganese SOD in the mitochondria that rapidly dismutates O 2
Ϫ⅐ to H 2 O 2 , 20 the latter was used as an index of ROS production. Activation of UCP2 by rosiglitazone (1 or 5 nmol) significantly decreased H 2 O 2 level in the mitochondrial fraction of RVLM ( Figure  2A ). The reduction in mitochondrial H 2 O 2 detected 12 hours after administration of the PPAR␥ activator (5 nmol) was significantly reversed by comicroinjection into RVLM of GW9662 (100 or 500 pmol) ( Figure 2B ). Moreover, our third series of experiments showed that microinjection of rosiglitazone (1 or 5 nmol) bilaterally into RVLM resulted in a dose-related decrease in mean (M)SAP ( Figure 3A ), as measured by radiotelemetry under conscious conditions. This rosiglitazone-induced vasodepressor response, which was significant for at least 27 hours and returned to baseline 48 hours postinjection, was reversed by coadministration of GW9662 (500 pmol) into RVLM ( Figure 3B ). Transcriptional activation of UCP2, on the other hand, exerted minimal effect on HR (data not shown). Microinjection of rosiglitazone into areas adjacent to the confines of RVLM (eg, lateral reticular nucleus or spinal trigeminal nucleus) did not affect basal MSAP (ϩ3.6Ϯ2.4 versus Ϫ4.5Ϯ3.1 mm Hg, nϭ5) or HR (Ϫ5Ϯ3 versus Ϫ7Ϯ4 bpm, nϭ5). Furthermore, we found in a separate experiment that pressor response induced by L-glutamate (2 nmol) in RVLM of anesthetized animals was comparable before and after microinjection of rosiglitazone (ϩ16.3Ϯ2.5 versus ϩ18.7Ϯ3.0 mm Hg, nϭ4) into the RVLM.
NADPH Oxidase-Derived O 2 ؊⅐ Induces Transcriptional Upregulation of Mitochondrial UCP2 in RVLM
In our search for cellular signals that upregulate UCP2, we noted that an elevated production of O 2
Ϫ⅐ induces mitochondrial UCP expression. 21 Our previous work 17 further indicated that activation of NADPH oxidase by Ang II is an important source of O 2
Ϫ⅐ in RVLM. The fourth series of experiments therefore investigated whether NADPH oxi- 
dase-derived O 2
Ϫ⅐ upregulates mitochondrial UCP2 transcription in RVLM. Microinjection bilaterally into RVLM of Ang II (100 pmol) resulted in upregulation of UCP2 mRNA ( Figure 4A ) or protein ( Figure 4B ) expression in RVLM that endured at least 24 hours. The Ang II-induced increase in UCP2 mRNA or protein level, detected 12 or 24 hours postinjection, was significantly antagonized by coadministration into RVLM of a NADPH oxidase inhibitor, DPI (1 nmol), or a SOD mimetic, tempol (50 nmol). In addition, the Ang II-induced mitochondrial UCP2 protein upregulation was also blunted in animals that received p22 phox or p47 phox ASON (100 pmol; Figure 4C ), microinjected bilaterally into the RVLM 24 hours before Ang II administration, or in animals that received AdSOD1 or AdSOD2 ( Figure 4D ), but not AdCAT, 7 or 14 days after gene transfer. The specificity of our finding was further ascertained by the absence of the membranous p22 phox or cytosolic p47 phox in the mitochondrial fraction, and selective inhibition of protein expression by their respective ASON in the membranous or cytosolic fraction from RVLM (Online Figure I) .
Involvement of p38 MAPK in UCP2 Upregulation in RVLM by NADPH Oxidase-Derived O 2
؊⅐
We reported previously 16 
Phosphorylation of PGC-1␣ by p38 MAPK is Essential for UCP2 Upregulation in RVLM
By being phosphorylated on activation of p38 MAPK, 22 the nuclear coactivator PGC-1␣, a PPAR-interacting protein for the induction of UCP2, 18 presents itself as a reasonable interposing signal in the cascade of events that lead to Ϫ⅐ . Microinjection bilaterally into RVLM of Ang II (100 pmol) induced significant phosphorylation of PGC-1␣ at its threonine residue ( Figure 6A ) and an increase in the expression of PGC-1␣/PPAR␥ complexes ( Figure 6B ) in RVLM, examined 15, 30, or 60 minutes posttreatment. This Ang II-induced PGC-1␣ phosphorylation ( Figure 6A ) or the increase in association between PGC-1␣/PPAR␥ ( Figure 6B ), detected 30 minutes posttreatment, was significantly blunted by tempol (50 nmol) or SB203580 (500 nmol) but not U0126 (500 nmol).
Superoxide-Dependent Upregulation of Mitochondrial UCP2 in RVLM During Chronic Oxidative Stress
We reported previously that chronic infusion of Ang II induces p38 MAPK phosphorylation and oxidative stress in RVLM. 16 Our seventh series of experiments therefore examined whether expression of mitochondrial UCP2 is regulated by O 2
Ϫ⅐ under this condition of chronic oxidative stress. Com-pared with animals that received artificial cerebrospinal fluid (aCSF) infusion, protein expression of UCP2 in RVLM was significantly upregulated 7 days after animals were subject to ICV infusion of Ang II (100 g ⅐ L Ϫ1 ⅐ h Ϫ1 ) (Online Figure II) . This Ang II-induced UCP2 upregulation was blunted by microinjection bilaterally into RVLM of an Ang II type 1 receptor antagonist, losartan (2 nmol), or by gene transfer of AdSOD1 or AdSOD2 into RVLM (Online Figure II) .
UCP2 Protects Against Chronic Oxidative Stress in RVLM and Hypertension
Our eighth series of experiments established a causal role for O 2 Ϫ⅐ -dependent transcriptional activation of mitochondrial UCP2 in central cardiovascular regulation and ROS homeostasis in RVLM. Consistent to our previous findings, 16 chronic ICV infusion of Ang II (100 g ⅐ L Ϫ1 ⅐ h Ϫ1 ) for 7 days elicited a gradual increase in MSAP that became significant between days 5 and 7 ( Figure 7A ). The Ang II-induced long-term pressor response was significantly potentiated in animals subject to microinjection bilaterally into RVLM of UCP2 ASON (100 pmol), but not UCP2 sense oligonucleotide (SON) (100 pmol), given on day 4 after infusion of the octapeptide. On the other hand, concomitant intracisternal infusion of rosiglitazone (1 or 5 g ⅐ L Ϫ1 ⅐ h Ϫ1 ) by osmotic minipump for 7 days, which increased UCP2 protein expression in the mitochondrial but not cytosolic fraction from RVLM (Online Figure III) , significantly attenuated the longterm pressor response ( Figure 7B ) that was reversed by UCP2 ASON treatment ( Figure 7C ). In addition, whereas gene knockdown of UCP2 (100 pmol) in RVLM enhanced, chronic infusion of rosiglitazone blunted the elevated tissue level of mitochondrial H 2 O 2 in RVLM detected on day 7 after Ang II infusion ( Figure 7D ).
Endogenous UCP2 Does Not Tonically Affect Mitochondrial H 2 O 2 Level in RVLM or SAP
We further used gene knockdown to decipher whether endogenous UCP2 in RVLM exerts a tonic regulatory effect on ROS level and cardiovascular functions. Microinjection bilaterally into RVLM of UCP2 ASON (100 pmol), similar to SON (100 pmol), elicited no significant alterations in mito-chondrial H 2 O 2 level in RVLM, examined 6, 12, or 24 hours posttreatment (Online Figure IV, A) . Likewise, basal MSAP (Online Figure IV 
Transcriptional Up-or Downregulation of Mitochondrial UCP2 in RVLM Does Not Affect Mitochondrial Respiratory Enzyme Activity or ATP Production
Enzyme activity of mitochondrial respiratory complex I to V, NADH cytochrome c reductase, or succinate cytochrome c reductase, as well as tissue ATP content in RVLM, assessed 12 or 24 hours after microinjection bilaterally into RVLM of rosiglitazone (5 nmol) or UCP2 ASON (100 pmol), was comparable to those from their corresponding control groups (Online Figure V ).
Discussion
The present study provided novel evidence for an active role for mitochondrial UCP2 in RVLM in ROS homeostasis and central cardiovascular regulation under conditions of oxidative stress. Our results support the notion that mitochondrial UCP2 participates actively in a cellular adaptive program for feedback control of ROS production in RVLM and the associated neurogenic hypertension during oxidative stress. To our knowledge, this is the first report that unveils the functional significance of mitochondrial UCP2 in protection against brain oxidative stress-associated hypertension.
Several antioxidant systems are present in the cell to counteract oxidative effects and to restore redox balance. In addition to the documented ROS scavenging enzymes and low molecular weight antioxidants, whether mitochondrial UCP functions as a natural antioxidant defense against oxidative stress is still debatable. 23 The present study provided novel in vivo evidence to support an antioxidant role for UCP2 and revealed its functional significance in neural control of cardiovascular phenotype. We found in RVLM, where mitochondrial oxidative stress plays a pivotal role in neural mechanism of hypertension, 19 that the rosiglitazonepromoted decrease in H 2 O 2 level was completely reversed by the PPAR␥ inhibitor GW9662 at a time point when MSAP was statistically insignificant from vehicle controls. Furthermore, observations of temporally correlated sequential upregulation of UCP2 mRNA and protein by rosiglitazone at low dose, together with the antagonism of the prolong duration of rosiglitazone-induced hypotension by gene knockdown of UCP2, strongly support the notion that transcriptional upregulation of mitochondrial UCP2 underpins the reduction in mitochondrial H 2 O 2 and the induced hypotension. These observations also deemed unlikely the possibility that the effects demonstrated are the consequences to a potential pleiotropic action of rosiglitazone. 24 A less than 20% decrease in mitochondrial membrane potential by UCP is able to inhibit H 2 O 2 production by more than 50%. 25 Mitochondrial ROS production in the brain is also significantly lower in transgenic mice that overexpress UCP2 26 or after adenovirus-mediated gene transfer of UCP2 in aortic endothelial cells. 12 It is generally accepted that O 2 Ϫ⅐ induces expression of UCPs, including UCP2, 21 although the underlying cellular events remain largely unknown. In this regard, we reported previously 17 that Ang II induces O 2 Ϫ⅐ in RVLM via activation of NADPH oxidase. The present study took advantage of this cellular event to unveil the molecular mechanism that underlies the O 2
Ϫ⅐ -dependent transcriptional upregulation of mitochondrial UCP2. We found that Ang II at a dose that induces O 2
Ϫ⅐ production 17 also increased UCP2 mRNA and protein expression in RVLM. The delayed antagonism of Ang II-induced UCP2 protein upregulation 24 hours after treat-ment with the NADPH oxidase inhibitor DPI or the SOD mimetic tempol, together with the blockade of Ang IIinduced UCP2 mRNA expression 12 hours after the same treatment, again suggests that NADPH oxidase-derived O 2 Ϫ⅐ regulates UCP2 protein expression at the transcription level. It is intriguing to note that the Ang II-induced UCP2 upregulation was significantly blunted by p22 phox or p47 phox ASON and gene transfer of AdSOD1, indicating that O 2 Ϫ⅐ derived from extramitochondrial compartments may play an active role in transcriptional upregulation of mitochondrial UCP2 in RVLM. The extramitochondrial origin of the NADPH oxidase-derived O 2 Ϫ⅐ was further confirmed by observations that p22 phox and p47 phox subunits are only found in the membranous and cytosolic fractions from RVLM. In myocardium of the failing heart, upregulation of UCP2 is closely associated with an increase in NADPH oxidasederived O 2
Ϫ⅐ . 27 Furthermore, we found that dismutation of O 2
Ϫ⅐ to H 2 O 2 by the SOD1 transgene reversed, whereas conversion of H 2 O 2 to H 2 O after overexpression of catalase by gene transfer did not affect the Ang II-induced UCP2 upregulation. These observations are interpreted to suggest that it is Ang II-induced O 2
Ϫ⅐ but not H 2 O 2 that induces the expression of mitochondrial UCP2 in RVLM. It is noteworthy that Ang II-induced UCP2 upregulation was also appreciably blunted by overexpression of SOD2 transgene in the RVLM. These results indicate that in addition to extramitochondrial sources, UCP2 expression may be regulated by O 2 Ϫ⅐ generated in the mitochondrial compartment. We recognize that O 2
Ϫ⅐ derived from xanthine oxidase increases the expression of UCP3, a homolog of UCP2 in skeletal muscle cells. 28 
Whereas its role in O 2
Ϫ⅐ -dependent transcriptional upregulation of mitochondrial UCP2 in RVLM remains to be identified, we noted that that xanthine oxidase plays a minor role in Ang II-induced O 2 Ϫ⅐ production. 17, 29 The O 2
Ϫ⅐ -induced UCP2 expression is not antagonized by inhibitors of mitochondrial ATP-sensitive potassium channel, adenine translocase, or mitochondrial permeability transition pores, suggesting that it is specific to the UCP. 20 We reported previously 16, 17 that activation of p38 MAPK and ERK1/2 underlies the manifestation of Ang II-induced cellular responses in RVLM via NADPH oxidase-derived O 2
Ϫ⅐ . Of those 2 MAPKs, the present study demonstrated that p38 MAPK, but not ERK1/2, acts as a key regulator of O 2
Ϫ⅐dependent UCP2 transcription in RVLM under oxidative stress. We found that p38 MAPK inhibitor (SB203580), but not ERK1/2 inhibitor (U0126), significantly prevented the Ang II-induced upregulation of mitochondrial UCP2 mRNA or protein. Our results further indicated that the induction of UCP2 transcription by p38 MAPK is accomplished at 2 levels: phosphorylation of threonine residue of the PPAR␥ coactivator, PGC-1␣, and enhancement of the ability of the latter to bind with PPAR␥. Activated p38 MAPK directly phosphorylates PGC-1␣ at its threonine 262, serine 265, and threonine 298 residues. 25 The resultant potentiation of PGC-1␣ docking to PPAR␥ 25 leads to a conformational change that permits the induction of UCPs by its transcription factors. 30 Our observations of an increase in formation of PGC-1␣/PPAR␥ complex in nuclear extract from RVLM after Ang II in a p38 MAPK-dependent manner are in line with those observations.
Functional evaluations in the present study further demonstrated, for the first time, that O 2
Ϫ⅐ -dependent transcriptional upregulation of mitochondrial UCP2 in RVLM plays an active role in feedback antagonism of oxidative stress and the associated hypertension. Production of O 2
Ϫ⅐ and H 2 O 2 via activation of NADPH oxidase in RVLM plays an important role in mediating chronic pressor response after ICV infusion of Ang II. 16 Using a loss-of-function approach, we found that Ang II-induced production of mitochondrial H 2 O 2 and chronic pressor response were further augmented after gene knock down of UCP2 in RVLM by its ASON. Conversely, gain-of-function experiments revealed that transcriptional upregulation of mitochondrial UCP2 in RVLM by acute and chronic administration of the PPAR␥ activator rosiglitazone attenuated the tissue level of H 2 O 2 and ameliorated the pressor response induced by Ang II. In addition, UCP2 gene knockdown attenuated the rosiglitazone-promoted inhibition of Ang II-induced hypertension. These results, together with our demonstration of a minor role for endogenous UCP2 at RVLM in regulation of basal ROS production and SAP, strongly support the notion that O 2
Ϫ⅐ -dependent transcriptional upregulation of mitochondrial UCP2 in RVLM participates actively in a feedback adaptive program to reduce ROS production in RVLM and hypertension associated with chronic oxidative stress. Rosiglitazone treatment was reported to reduce blood pressure in hypertensive patients 31 via reduction in ROS production in the vascular smooth muscle cells 32 or endothelial cells. 33 Our observations that rosiglitazone-induced vasodepressor response returned to baseline values 48 hours postinjection and that application of the PPAR␥ activator into areas adjacent to the confine of RVLM did not affect basal MSAP and HR suggest that the elicited cardiovascular responses were not the results of nonspecific neuro-cardiovascular toxicity. The elicitation of similar degree of pressor response by L-glutamate in RVLM before and after rosiglitazone treatment further indicates that the neural circuitry is functionally intact following transcriptional activation of UCP2. Because ICV Ang II infusion resulted in an increase in MSAP under the condition of UCP2 upregulation in RVLM, oxidative stress in other areas of brain may also participate in central Ang II-induced hypertension. In this regard, oxidative stress in the subfornical 34 and hypothalamic areas 35 in the forebrain also contributes to neural mechanism of Ang II-induced hypertension.
Our observation that transcriptional up-or downregulation of UCP2 exerted minimal effects on mitochondrial electron transport chain activity and tissue ATP content in RVLM implies that the primary function of UCP2 is not to promote gross thermogenesis or energetic inefficiency in the mitochondria of RVLM. This notion is in concordance with the consensus that a "mild" uncoupling caused by activation of UCP2 leads only to limited increases in proton conductance in the inner membrane of mitochondria, resulting in slightly increased oxidative phosphorylation rate but maintained production of ATP. 36, 37 These observations also deemed unlikely the possibility that the regulatory actions of UCP2 on ROS level and hemodynamic functions are secondary to induced bioenergetic deficiency in RVLM. We reported recently 19 that impairment of mitochondrial electron transport chain activity increases O 2
Ϫ⅐ , leading to chronic oxidative stress in RVLM. Because UCP2 exerted minimal effects on electron transport chain activity, it is unlikely that this source of ROS is the target for its antioxidant effect. UCP2 is engaged in regulation of redox balance by decreasing proton electrochemical gradient across the inner mitochondrial membrane. 6, 8 It follows that UCP2 may exert its antioxidant actions via this mode of mitochondrial action.
We recognize that results obtained from the mitochondrial fractions in this study depend on the purity of our preparations. In this regard, isolation of brain mitochondria by discontinuous Percoll density gradient 38 has been reported to yield approximately 90% recognizable mitochondria with little contamination of other organelles. We also confirmed the purity of the isolated mitochondria by showing a lack of cytosolic marker proteins in the mitochondrial fraction. We are also aware that acute injection of reagents such as tempol or DPI exerted effects on UCP2 expression 12 or 24 hours after administration. We interpret these seemingly longlasting pharmacological effects by noting that the signaling cascade that interposes between stimulation of angiotensin type 1 receptor by Ang II, production of NADPH oxidasederived O 2 Ϫ⅐ , activation of p38 MAPK, and transcriptional upregulation of UCP2 requires 12 to 24 hours to materialize. It follows that the same amount of time is required to manifest the effects of interrupting individual steps in this signaling cascade by tempol (O 2 Ϫ⅐ ) or DPI (NADPH oxidase) on Ang II-induced UCP2 expression.
In conclusion, the present study provided the first in vivo evidence for a direct link between brain mitochondrial UCP2 and central regulation of arterial pressure. Specifically, we demonstrated that transcriptional upregulation of mitochondrial UCP2 activated by an elevation in mitochondrial and NADPH oxidase-derived extramitochondrial O 2
Ϫ⅐ plays an active role in feedback regulation of ROS production in RVLM and hypertension associated with chronic oxidative stress (Figure 8) . Epigenetic studies reported a positive association between UCP2 gene polymorphism and increased oxidative stress in patients with hypertension. 39 Because of the important role of mitochondrial oxidative stress in RVLM in neural mechanism of hypertension, 19 our observed antioxidant action of mitochondrial UCP2 is of considerable importance in protection against neurogenic hypertension associated with brain oxidative stress. Our results also suggest the possibility of UCP2 as a target molecule for investigations on the etiology and treatment of neurogenic hypertension. 
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